AbbVie Inc
ABBV226.710USD
+3.890+1.75%
Fechamento 12/19, 16:00（ET）Cotações atrasadas em 15 min
400.68BValor de mercado
170.81P/L TTM
Mais detalhes de AbbVie Inc Empresa
AbbVie Inc. is a global, diversified research-based biopharmaceutical company. It is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. Its product portfolio includes Immunology, Oncology, Aesthetics, Neuroscience, Eye Care and Other Key Products. Immunology products include rheumatology, dermatology and gastroenterology. Oncology products include Imbruvica, Venclexta/Venclyxto, Elahere and Epkinly. Aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Its Neuroscience products include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy, and Qulipta. Eye Care products include Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, and other eye care. Other key products include Mavyret/Maviret, Creon, and Linzess/Constella. Its investigational candidate, bretisilocin, is for the treatment of patients with moderate-to-severe major depressive disorder (MDD).
Informações de AbbVie Inc
Código da empresaABBV
Nome da EmpresaAbbVie Inc
Data de listagemJan 02, 2013
CEOMichael (Robert A)
Número de funcionários55000
Tipo de títulosOrdinary Share
Fim do ano fiscalJan 02
Endereço1 N Waukegan Rd
CidadeNORTH CHICAGO
Bolsa de valoresNASDAQ OMX NASDAQ Basic NYSE
PaísUnited States of America
Código postal60064
Telefone18479327900
Sitehttps://www.abbvie.com/
Código da empresaABBV
Data de listagemJan 02, 2013
CEOMichael (Robert A)
Executivos da empresa AbbVie Inc
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Azita Saleki-Gerhardt, Ph.D.
Dr. Azita Saleki-Gerhardt, Ph.D.
Executive Vice President, Chief Operations Officer
Executive Vice President, Chief Operations Officer
183.77K
--
Mr. Thomas C. (Tom) Freyman, CPA
Mr. Thomas C. (Tom) Freyman, CPA
Independent Director
Independent Director
134.63K
+0.90%
Mr. Edward J. (Ed) Rapp
Mr. Edward J. (Ed) Rapp
Independent Director
Independent Director
42.95K
+2.88%
Dr. Roopal Thakkar, M.D.
Dr. Roopal Thakkar, M.D.
Executive Vice President - Research & Development, Chief Scientific Officer
Executive Vice President - Research & Development, Chief Scientific Officer
42.28K
+16.15%
Ms. Roxanne S. Austin, CPA
Ms. Roxanne S. Austin, CPA
Lead Independent Director
Lead Independent Director
38.46K
+3.23%
Dr. Robert J. Alpern, M.D.
Dr. Robert J. Alpern, M.D.
Independent Director
Independent Director
35.65K
+3.49%
Mr. Frederick H. (Rick) Waddell
Mr. Frederick H. (Rick) Waddell
Independent Director
Independent Director
28.96K
+4.33%
Ms. Melody B. Meyer
Ms. Melody B. Meyer
Independent Director
Independent Director
16.50K
+7.87%
Mr. Timothy J. Richmond
Mr. Timothy J. Richmond
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
6.13K
-77.61%
Ms. Jennifer L. Davis
Ms. Jennifer L. Davis
Independent Director
Independent Director
2.52K
+91.00%
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Azita Saleki-Gerhardt, Ph.D.
Dr. Azita Saleki-Gerhardt, Ph.D.
Executive Vice President, Chief Operations Officer
Executive Vice President, Chief Operations Officer
183.77K
--
Mr. Thomas C. (Tom) Freyman, CPA
Mr. Thomas C. (Tom) Freyman, CPA
Independent Director
Independent Director
134.63K
+0.90%
Mr. Edward J. (Ed) Rapp
Mr. Edward J. (Ed) Rapp
Independent Director
Independent Director
42.95K
+2.88%
Dr. Roopal Thakkar, M.D.
Dr. Roopal Thakkar, M.D.
Executive Vice President - Research & Development, Chief Scientific Officer
Executive Vice President - Research & Development, Chief Scientific Officer
42.28K
+16.15%
Ms. Roxanne S. Austin, CPA
Ms. Roxanne S. Austin, CPA
Lead Independent Director
Lead Independent Director
38.46K
+3.23%
Dr. Robert J. Alpern, M.D.
Dr. Robert J. Alpern, M.D.
Independent Director
Independent Director
35.65K
+3.49%
Detalhamento da receita
Moeda: USDAtualizado em: seg, 6 de out
Moeda: USDAtualizado em: seg, 6 de out
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
Por EmpresaUSD
Nome
Receita
Proporção
Immunology-SKYRIZI
4.42B
28.20%
Immunology-RINVOQ
2.03B
12.93%
Immunology-HUMIRA
1.18B
7.52%
Hematologic Oncology-IMBRUVICA
965.00M
6.15%
Neuroscience-Botox Therapeutic
928.00M
5.92%
Outro
6.16B
39.27%
Por RegiãoUSD
Nome
Receita
Proporção
United States
11.34B
72.31%
International
3.48B
22.18%
All other countries
603.00M
3.84%
Collaboration revenue
260.00M
1.66%
Por Empresa
Por Região
Por EmpresaUSD
Nome
Receita
Proporção
Immunology-SKYRIZI
4.42B
28.20%
Immunology-RINVOQ
2.03B
12.93%
Immunology-HUMIRA
1.18B
7.52%
Hematologic Oncology-IMBRUVICA
965.00M
6.15%
Neuroscience-Botox Therapeutic
928.00M
5.92%
Outro
6.16B
39.27%
Distribuição de ações
Atualizado em: dom, 16 de nov
Atualizado em: dom, 16 de nov
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
The Vanguard Group, Inc.
10.01%
BlackRock Institutional Trust Company, N.A.
5.25%
State Street Investment Management (US)
4.52%
Geode Capital Management, L.L.C.
2.29%
JP Morgan Asset Management
2.06%
Outro
75.87%
Investidores
Investidores
Proporção
The Vanguard Group, Inc.
10.01%
BlackRock Institutional Trust Company, N.A.
5.25%
State Street Investment Management (US)
4.52%
Geode Capital Management, L.L.C.
2.29%
JP Morgan Asset Management
2.06%
Outro
75.87%
Tipos de investidores
Investidores
Proporção
Investment Advisor
43.73%
Investment Advisor/Hedge Fund
20.55%
Research Firm
3.07%
Bank and Trust
2.37%
Pension Fund
2.27%
Sovereign Wealth Fund
1.41%
Hedge Fund
0.92%
Insurance Company
0.70%
Family Office
0.20%
Outro
24.78%
Participação acionária institucional
Atualizado em: seg, 8 de dez
Atualizado em: seg, 8 de dez
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q4
5311
1.33B
74.86%
+1.37M
2025Q3
5386
1.32B
74.95%
+8.86M
2025Q2
5326
1.32B
74.78%
+2.41M
2025Q1
5334
1.32B
74.15%
+3.84M
2024Q4
5267
1.31B
73.92%
+9.35M
2024Q3
4970
1.30B
74.13%
-1.24M
2024Q2
4907
1.30B
73.33%
+14.47M
2024Q1
4916
1.28B
72.48%
+1.37M
2023Q4
4861
1.27B
72.12%
+10.24M
2023Q3
4666
1.27B
72.28%
+8.75M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
The Vanguard Group, Inc.
176.50M
9.99%
+3.35M
+1.94%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
92.10M
5.21%
+1.07M
+1.18%
Jun 30, 2025
State Street Investment Management (US)
80.02M
4.53%
+61.16K
+0.08%
Jun 30, 2025
Geode Capital Management, L.L.C.
39.18M
2.22%
+924.76K
+2.42%
Jun 30, 2025
JP Morgan Asset Management
37.47M
2.12%
+1.87M
+5.24%
Jun 30, 2025
Charles Schwab Investment Management, Inc.
26.78M
1.52%
+1.52M
+6.01%
Jun 30, 2025
Capital Research Global Investors
25.27M
1.43%
-8.24M
-24.60%
Jun 30, 2025
Morgan Stanley Smith Barney LLC
23.51M
1.33%
+254.93K
+1.10%
Jun 30, 2025
Norges Bank Investment Management (NBIM)
23.10M
1.31%
-1.99M
-7.94%
Jun 30, 2025
Fidelity Management & Research Company LLC
19.65M
1.11%
-1.78M
-8.30%
Jun 30, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 6 de dez
Atualizado em: sáb, 6 de dez
Nome
Proporção
VanEck Pharmaceutical ETF
9.64%
First Trust NASDAQ Pharmaceuticals ETF
8.05%
Health Care Select Sector SPDR Fund
7.89%
Proshares Ultra Health Care
7.62%
iShares U.S. Healthcare ETF
7.57%
JPMorgan Healthcare Leaders ETF
6.87%
Simplify Health Care ETF
6.73%
Fidelity MSCI Health Care Index ETF
6.5%
Harbor Health Care ETF
6.18%
iShares Core High Dividend ETF
5.9%
Ver Mais
VanEck Pharmaceutical ETF
Proporção9.64%
First Trust NASDAQ Pharmaceuticals ETF
Proporção8.05%
Health Care Select Sector SPDR Fund
Proporção7.89%
Proshares Ultra Health Care
Proporção7.62%
iShares U.S. Healthcare ETF
Proporção7.57%
JPMorgan Healthcare Leaders ETF
Proporção6.87%
Simplify Health Care ETF
Proporção6.73%
Fidelity MSCI Health Care Index ETF
Proporção6.5%
Harbor Health Care ETF
Proporção6.18%
iShares Core High Dividend ETF
Proporção5.9%
Dividendo
Um total de
48.58B
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Oct 31, 2025
ABBV.NB Interim Cash Dividend of gross USD 1.73 paid on Feb 17, 2026 going ex on Jan 16, 2026 with reinvestment option
Jan 16, 2026
Feb 17, 2026
Jan 16, 2026
Sep 05, 2025
ABBV.NB Final Cash Dividend of gross USD 1.64 paid on Nov 14, 2025 going ex on Oct 15, 2025 with reinvestment option
Oct 15, 2025
Nov 14, 2025
Oct 15, 2025
Jun 20, 2025
ABBV.NB Interim Cash Dividend of gross USD 1.64 paid on Aug 15, 2025 going ex on Jul 15, 2025 with reinvestment option
Jul 15, 2025
Aug 15, 2025
Jul 15, 2025
Feb 13, 2025
ABBV.NB Interim Cash Dividend of gross USD 1.64 paid on May 15, 2025 going ex on Apr 15, 2025 with reinvestment option
Apr 15, 2025
May 15, 2025
Apr 15, 2025
Oct 30, 2024
ABBV.NB Interim Cash Dividend of gross USD 1.64 paid on Feb 14, 2025 going ex on Jan 15, 2025 with reinvestment option
Jan 15, 2025
Feb 14, 2025
Jan 15, 2025
Oct 30, 2024
ABBV.NB Interim Cash Dividend of gross USD 1.64 paid on Feb 14, 2025 going ex on Jan 15, 2025
Jan 15, 2025
Feb 14, 2025
Jan 15, 2025
Sep 06, 2024
ABBV.NB Final Cash Dividend of gross USD 1.55 paid on Nov 15, 2024 going ex on Oct 15, 2024 with reinvestment option
Oct 15, 2024
Nov 15, 2024
Oct 15, 2024
Jun 21, 2024
ABBV.NB Interim Cash Dividend of gross USD 1.55 paid on Aug 15, 2024 going ex on Jul 15, 2024 with reinvestment option
Jul 15, 2024
Aug 15, 2024
Jul 15, 2024
Feb 15, 2024
ABBV.NB Interim Cash Dividend of gross USD 1.55 paid on May 15, 2024 going ex on Apr 12, 2024 with reinvestment option
Apr 15, 2024
May 15, 2024
Apr 12, 2024
Oct 27, 2023
ABBV.NB Interim Cash Dividend of gross USD 1.55 paid on Feb 15, 2024 going ex on Jan 12, 2024 with reinvestment option
Jan 16, 2024
Feb 15, 2024
Jan 12, 2024
Ver Mais
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
Perguntas frequentes
Quem são os cinco principais acionistas de AbbVie Inc?
Os cinco principais acionistas de AbbVie Inc são:
The Vanguard Group, Inc. detém 176.50M Ações, representando 9.99% do total de Ações.
BlackRock Institutional Trust Company, N.A. detém 92.10M Ações, representando 5.21% do total de Ações.
State Street Investment Management (US) detém 80.02M Ações, representando 4.53% do total de Ações.
Geode Capital Management, L.L.C. detém 39.18M Ações, representando 2.22% do total de Ações.
JP Morgan Asset Management detém 37.47M Ações, representando 2.12% do total de Ações.
The Vanguard Group, Inc. detém 176.50M Ações, representando 9.99% do total de Ações.
BlackRock Institutional Trust Company, N.A. detém 92.10M Ações, representando 5.21% do total de Ações.
State Street Investment Management (US) detém 80.02M Ações, representando 4.53% do total de Ações.
Geode Capital Management, L.L.C. detém 39.18M Ações, representando 2.22% do total de Ações.
JP Morgan Asset Management detém 37.47M Ações, representando 2.12% do total de Ações.
Quais são os três principais tipos de acionistas de AbbVie Inc?
Os três principais tipos de acionistas da AbbVie Inc são:
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
State Street Investment Management (US)
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
State Street Investment Management (US)
Quantas instituições possuem ações da AbbVie Inc (ABBV)?
Em 2025Q4, 5311 instituições possuíam ações da AbbVie Inc, com valor de mercado aproximado de 1.33B, representando 74.86% do total de ações. Em comparação com 2025Q3, a participação institucional aumentou em -0.10%.
Qual é a maior fonte de receita da AbbVie Inc?
Em FY2025Q2, o segmento de negócios Immunology-SKYRIZI gerou a maior receita para AbbVie Inc, totalizando 4.42B e representando 28.20% da receita total.
